8-K Announcements
6Material company update
Mar 2, 2026·SEC
Material company update
Nov 5, 2025·SEC
Material company update
Aug 11, 2025·SEC
Sionna Therapeutics, Inc.(SION)Earnings, Financials & Key Ratios
SION•NASDAQ
$43.29
$1.94B mkt cap·Price updated May 6, 2026
AboutSionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.Show more
- Revenue$0
- EBITDA-$88M-26.4%
- Net Income-$75M-22.0%
- EPS (Diluted)-1.88-34.3%
- ROE-105.18%
- ROIC-204.38%
- Debt/Equity0.03
SION Key Insights
Sionna Therapeutics, Inc. (SION) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Share count reduced 9.4% through buybacks
✗Weaknesses
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SION Price & Volume
Sionna Therapeutics, Inc. (SION) stock price & volume — 10-year historical chart
Loading chart...
SION Growth Metrics
Sionna Therapeutics, Inc. (SION) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-58.71%
5 Years-58.71%
3 Years-60.85%
Last Year-36.35%
SION Recent Earnings
Sionna Therapeutics, Inc. (SION) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/6 qtrs (60%)
Q2 2026Latest
Mar 2, 2026EPS
$0.46
Est $0.54
+14.7%
Revenue
—
Q4 2025
Nov 5, 2025EPS
$0.46
Est $0.52
+11.5%
Revenue
—
Q3 2025
Aug 11, 2025EPS
$0.41
Est $0.68
+39.7%
Revenue
—
Q2 2025
May 12, 2025EPS
$0.62
Est $0.45
-37.8%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 2, 2026 | $0.46vs $0.54+14.7% | — |
| Q4 2025 | Nov 5, 2025 | $0.46vs $0.52+11.5% | — |
| Q3 2025 | Aug 11, 2025 | $0.41vs $0.68+39.7% | — |
| Q2 2025 | May 12, 2025 | $0.62vs $0.45-37.8% | — |
Based on last 6 quarters of dataView full earnings history →
SION Peer Comparison
Sionna Therapeutics, Inc. (SION) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 VRTX | 108.78B | 427.65 | 27.91 | 9.57% | 35.4% | 23.93% | 0.21 | |
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% | ||
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% | |||
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 KRYS | 8.52B | 288.90 | 42.24 | 33.94% | 53.92% | 19.25% | 0.01 | |
 GILD | 169.83B | 136.30 | 358.68 | 6.04% | 28.9% | 37.62% | 1.39 | |
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 | |
 IONS | 12.7B | 76.85 | -32.29 | 33.87% | -30.87% | -58.57% | 5.35 |
Compare SION vs Peers
Sionna Therapeutics, Inc. (SION) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SION Income Statement
Sionna Therapeutics, Inc. (SION) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 668K | 647K |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | -668K▲ 0% | -647K▲ 3.1% |
| Gross Margin % | - | - | - | - |
| Gross Profit Growth % | - | - | - | 3.14% |
| Operating Expenses | 41.37M | 50.33M | 69.89M | 88.33M |
| OpEx % of Revenue | - | - | - | - |
| Selling, General & Admin | 6.77M | 9.71M | 13.27M | 28.72M |
| SG&A % of Revenue | - | - | - | - |
| Research & Development | 34.6M | 40.63M | 57.29M | 60.26M |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | 0 | 0 | -668K | -647K |
| Operating Income | -41.37M▲ 0% | -50.33M▼ 21.7% | -70.56M▼ 40.2% | -88.98M▼ 26.1% |
| Operating Margin % | - | - | - | - |
| Operating Income Growth % | - | -21.66% | -40.18% | -26.12% |
| EBITDA | -41.25M | -49.75M | -69.89M | -88.33M |
| EBITDA Margin % | - | - | - | - |
| EBITDA Growth % | - | -20.61% | -40.48% | -26.4% |
| D&A (Non-Cash Add-back) | 122K | 583K | 668K | 647K |
| EBIT | -41.37M | -50.33M | -70.56M | -75.27M |
| Net Interest Income | 1.13M | 2.77M | 8.17M | 13.29M |
| Interest Income | 1.13M | 2.77M | 8.17M | 13.29M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income/Expense | 1.13M | 3.07M | 8.87M | 13.71M |
| Pretax Income | -40.24M▲ 0% | -47.26M▼ 17.5% | -61.69M▼ 30.5% | -75.27M▼ 22.0% |
| Pretax Margin % | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% |
| Net Income | -40.24M▲ 0% | -47.26M▼ 17.5% | -61.69M▼ 30.5% | -75.27M▼ 22.0% |
| Net Margin % | - | - | - | - |
| Net Income Growth % | - | -17.45% | -30.52% | -22.01% |
| Net Income (Continuing) | -40.24M | -47.26M | -61.69M | -75.27M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.91▲ 0% | -1.07▼ 17.4% | -1.40▼ 30.7% | -1.88▼ 34.3% |
| EPS Growth % | - | -17.45% | -30.71% | -34.29% |
| EPS (Basic) | -0.91 | -1.07 | -1.40 | -1.88 |
| Diluted Shares Outstanding | 44.12M | 44.12M | 44.12M | 39.96M |
| Basic Shares Outstanding | 44.12M | 44.12M | 44.12M | 39.96M |
| Dividend Payout Ratio | - | - | - | - |
SION Balance Sheet
Sionna Therapeutics, Inc. (SION) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|
| Total Current Assets | 83.83M | 39.21M | 150.99M | 241.42M |
| Cash & Short-Term Investments | 82.61M | 38.52M | 147.54M | 235.88M |
| Cash Only | 54.84M | 38.52M | 37.79M | 58.45M |
| Short-Term Investments | 27.77M | 0 | 109.75M | 177.43M |
| Accounts Receivable | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - |
| Other Current Assets | 1.22M | 686K | 3.46M | 5.54M |
| Total Non-Current Assets | 3.54M | 12.74M | 34.76M | 84.53M |
| Property, Plant & Equipment | 2.57M | 11.73M | 10.3M | 9.15M |
| Fixed Asset Turnover | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 20.5M | 0 |
| Other Non-Current Assets | 962K | 1.01M | 3.96M | 75.38M |
| Total Assets | 87.37M▲ 0% | 51.95M▼ 40.5% | 185.75M▲ 257.6% | 325.95M▲ 75.5% |
| Asset Turnover | - | - | - | - |
| Asset Growth % | - | -40.55% | 257.59% | 75.48% |
| Total Current Liabilities | 8.25M | 8.04M | 10.42M | 11.71M |
| Accounts Payable | 557K | 719K | 1.19M | 769K |
| Days Payables Outstanding | - | - | 648.04 | 433.83 |
| Short-Term Debt | 0 | 0 | 0 | 1.27M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.95M | 3.11M | 2.97M | 9.67M |
| Current Ratio | 10.16x | 4.88x | 14.49x | 20.61x |
| Quick Ratio | 10.16x | 4.88x | 14.49x | 20.61x |
| Cash Conversion Cycle | - | - | - | - |
| Total Non-Current Liabilities | 149.04M | 158.79M | 339.05M | 7.41M |
| Long-Term Debt | 0 | 0 | 0 | 7.41M |
| Capital Lease Obligations | 0 | 9.75M | 8.68M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 149.04M | 149.04M | 330.37M | 0 |
| Total Liabilities | 157.29M | 166.83M | 349.46M | 19.12M |
| Total Debt | 0 | 10.48M | 9.75M | 8.68M |
| Net Debt | -54.84M | -28.04M | -28.04M | -49.77M |
| Debt / Equity | - | - | - | 0.03x |
| Debt / EBITDA | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - |
| Interest Coverage | - | - | - | - |
| Total Equity | -69.92M▲ 0% | -114.88M▼ 64.3% | -163.71M▼ 42.5% | 306.83M▲ 287.4% |
| Equity Growth % | - | -64.29% | -42.51% | 287.42% |
| Book Value per Share | -1.58 | -2.60 | -3.71 | 7.68 |
| Total Shareholders' Equity | -69.92M | -114.88M | -163.71M | 306.83M |
| Common Stock | 2K | 2K | 5K | 45K |
| Retained Earnings | -72.14M | -119.4M | -181.09M | -256.35M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | -16K | 0 | 368K | 540K |
| Minority Interest | 0 | 0 | 0 | 0 |
SION Cash Flow Statement
Sionna Therapeutics, Inc. (SION) cash flow — operating, investing & free cash flow history
| Line item | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|
| Cash from Operations | -36.07M | -43.7M | -52.79M | -66.3M |
| Operating CF Margin % | - | - | - | - |
| Operating CF Growth % | - | -21.16% | -20.8% | -25.59% |
| Net Income | -40.24M | -47.26M | -61.69M | -75.27M |
| Depreciation & Amortization | 122K | 583K | 668K | -3.05M |
| Stock-Based Compensation | 1.69M | 2.26M | 3.71M | 12.07M |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -400K | 1.5M | 7.6M | 2.61M |
| Working Capital Changes | 2.76M | -783K | -3.08M | -2.65M |
| Change in Receivables | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | -1.51M | 162K | 467K | -417K |
| Cash from Investing | -29.26M | 27.35M | -126.91M | -118.75M |
| Capital Expenditures | -1.87M | -1.12M | -27K | -377K |
| CapEx % of Revenue | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 |
| Cash from Financing | 110.86M | 31K | 178.97M | 205.71M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 0 | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 |
| Other Financing | 64K | 31K | 0 | 0 |
| Net Change in Cash | 45.52M▲ 0% | -16.32M▼ 135.8% | -733K▲ 95.5% | 20.66M▲ 2919.1% |
| Free Cash Flow | -37.94M▲ 0% | -44.81M▼ 18.1% | -52.81M▼ 17.8% | -66.67M▼ 26.2% |
| FCF Margin % | - | - | - | - |
| FCF Growth % | - | -18.11% | -17.85% | -26.24% |
| FCF per Share | -0.86 | -1.02 | -1.20 | -1.67 |
| FCF Conversion (FCF/Net Income) | 0.90x | 0.92x | 0.86x | 0.88x |
| Interest Paid | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
SION Key Ratios
Sionna Therapeutics, Inc. (SION) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -105.18% |
| Return on Invested Capital (ROIC) | - | - | - | -204.38% |
| Debt / Equity | - | - | - | 0.03x |
| FCF Conversion | 0.90x | 0.92x | 0.86x | 0.88x |
SION SEC Filings & Documents
Sionna Therapeutics, Inc. (SION) SEC filings — annual & quarterly reports (10-K, 10-Q)
SION Frequently Asked Questions
Sionna Therapeutics, Inc. (SION) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Sionna Therapeutics, Inc. (SION) grew revenue by 0.0% over the past year. Growth has been modest.
Sionna Therapeutics, Inc. (SION) reported a net loss of $75.3M for fiscal year 2025.
Dividend & Returns
Sionna Therapeutics, Inc. (SION) has a return on equity (ROE) of -105.2%. Negative ROE indicates the company is unprofitable.
Sionna Therapeutics, Inc. (SION) had negative free cash flow of $66.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More SION
Sionna Therapeutics, Inc. (SION) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates